Rempex A Wholly Owned Sub Of Melinta Therapeutics Patent-Cliff Exposure & CMS Drug Spending Portfolio

Rempex A Wholly Owned Sub Of Melinta Therapeutics (US): 3 reconciled FDA prescription therapies, $2.4M 2024 CMS Part D & Medicaid spend, and 3 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies3
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2032-01-01
2024 CMS Total Public Spend$2.4M
2024 Medicare Part D Spend$1.9M
2024 Medicaid Spend$536K
California HCAI SB 17 Filings3 WAC filings (max 23.5% 2-yr change)